- Home
- ASBP vs OSRH Comparison
ASBP vs OSRH Comparison
Compare ASBP & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ASBP | OSRH |
|---|---|---|
| Founded | 2021 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0M | 15.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ASBP | OSRH |
|---|---|---|
| Price | $0.10 | $0.62 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 42.7M | 439.2K |
| Earning Date | 02-24-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,941.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.07 | $0.45 |
| 52 Week High | $15.80 | $12.54 |
Technical Indicators
Market Signals| Indicator | ASBP | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | 44.10 | 50.06 |
| Support Level | $0.10 | $0.55 |
| Resistance Level | $0.17 | $0.65 |
| Average True Range (ATR) | 0.02 | 0.06 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 13.83 | 46.60 |
Price Performance
Historical ComparisonAbout ASBP Aspire Biopharma Holdings Inc.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.
About OSRH OSR Holdings Inc.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.